South Korean biotech Sillajen was hit hard last week when its oncolytic virus therapy Pexa-Vec failed a phase 3 trial, but the company reckons it doesn’t spell the end of the program.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,